Press Releases | Medtronic

Month Year

Email alerts

Aug 22, 2017

Medtronic Reports First Quarter Financial Results

Revenue of $7.390 Billion Grew 3% as Reported; 4% at Constant Currency

DUBLIN - August 22, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2018, which ended July 28, 2017. The company reported first quarter...
Aug 21, 2017

Medtronic Receives CE Mark for Attain Stability(TM) Quad MRI SureScan(TM) Active-Fixation Heart Lead

Clinical Trial Also Underway in U.S., Canada and Other Geographies

DUBLIN - August 21, 2017 - Medtronic plc (NYSE: MDT) announced it has received CE (Conformité Européene) Mark for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with...
Aug 17, 2017

Medtronic EVP & CFO Karen L. Parkhill to Speak at Intellisight 2017 Conference

DUBLIN - August 17, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the CFA Society Minnesota's 6th Annual Investor Conference,...
Aug 15, 2017

Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2018

DUBLIN - August 15, 2017 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the first quarter fiscal year 2018 on Tuesday, August 22, 2017. A news release will...
Aug 14, 2017

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

First-of-its-Kind Randomized Clinical Trial Will Evaluate One-Month DAPT in Patients Following PCI Procedures with the Newer-Generation Durable Polymer Resolute Onyx DES

DUBLIN- August 14, 2017 - Medtronic plc (NYSE: MDT) today announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) - the combination of aspirin...
Aug 2, 2017

Medtronic Expands Heart Valve Portfolio with FDA Approval and CE Mark of the Avalus(TM) Surgical Aortic Valve

Introduction of New Pericardial Aortic Heart Valve in the U.S. and Europe Reinforces Company's Commitment to Comprehensive Solutions to Heart Valve Disease

DUBLIN - August 2, 2017 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus(TM) pericardial aortic...
Aug 1, 2017

FIRE AND ICE Trial Analysis Shows Medtronic Cryoballoon Reduces Healthcare System Costs and Utilization

Data from Landmark Trial Published in the Journal of the American Heart Association

DUBLIN - August 1, 2017 - A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc (NYSE: MDT), was published today in the Journal of the American Heart...
Jul 31, 2017

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

DUBLIN - July 31, 2017 - Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic...
Jul 30, 2017

Medtronic Completes Sale of a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health

DUBLIN - July 30, 2017 - Medtronic plc (NYSE: MDT) today announced that it has completed the previously announced sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional...
Jul 17, 2017

Five-Year Data Demonstrate InterStim(TM) Therapy Offers Sustained Long-Term Efficacy and Quality of Life Improvements for Overactive Bladder Patients

The InterStim System is the Only Proven, Long-Term Sacral Neuromodulation Solution for Overactive Active Bladder

DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of...

Show per page